Uterine cancer is a common form of cancer of the female reproductive system that initiates in the lining of the uterus. According to the American Cancer Society, around 47,130 new cases of endometrial cancer were diagnosed, and 8,010 women died from it in 2012.
The Europe Uterine Cancer Market is expected to grow modestly from USD 4,300 million in 2015, at a CAGR of 2-6%.
The Europe uterine cancer therapeutics & diagnostic market is segmented based on:
Furthermore, the diagnostics market is segmented under major tests such as:
Based on geography it is segmented as:
According to the surveys by WHO, incidences of endometrial cancer is greater in the developed regions such as the European countries due to the shifting lifestyle of women. Pervasiveness of uterine cancer is more in women aged 50 years and above.
Some of the key participants in the industry include Ariad Pharmaceuticals, Inc., Abbott Laboratories, Becton, Dickinson & Co., Merck & Co., Inc., GlaxoSmithKline Plc, Novartis AG, Sanofi, Siemens Healthcare Inc., Roche Ltd etc.
SPECIALITIES OF THIS REPORT
WHAT THE REPORT OFFERS
1.1 Market Definition
1.2 Research Methodology
2. Executive Summary
3. Market Overview
3.1 Market Drivers
3.1.1 Rise in awareness about Uterine diseases and their available therapies
3.1.2 Increasing health care expenditure
3.1.3 Innovation in drug development, and subsequent technological advancements
3.2 Market Restraints
3.2.1 Low success rate in clinical trails for cancer drugs
3.2.2 High cost associated with the treatment
3.2.3 Adverse side-effects of treatment and high toxicity of drugs
3.3 Market Opportunitites
3.4 Market Threats
4. Porters Five Force Analysis
4.1 Bargaining Power of suppliers
4.2 Bargaining power of buyers
4.3 Degree of competition
4.4 Threat of substitution
4.5 Threat of new entrants
5. Market Segmentation
5.1 Europe Uterine Cancer Therapeutics & Diagnostic Market, by Cancer Type
5.1.1 Uterine sarcomas
5.1.2 Endometrial carcinomas
220.127.116.11 Squamous cell carcinoma
5.2 Europe Uterine Cancer Therapeutics Market
5.2.3 Radiation therapy
5.2.5 Follow-up Treatment
5.3 Europe Uterine Cancer Diagnostics Market
5.3.2 Pelvic ultrasound.
5.3.4 Dilation and curettage
5.3.5 CT scan
5.4 Europe Uterine Cancer Therapeutics & Diagnostics Market, By Region
5.4.6 Rest Of Europe
6. Competitive Landscape
6.1 Mergers & Acquisitions
6.2 Agreements, Collaborations & Partnerships
6.3 New Product Launches
6.4 Recommendations to new market players
7. Company Profiles
7.1 Ariad Pharmaceuticals, Inc.
7.2 Abbott Laboratories
7.3 Becton, Dickinson & Co.
7.4 GlaxoSmithKline Plc
7.5 Merck & Co., Inc.
7.6 Novartis AG
7.8 Siemens Healthcare Inc
7.9 Roche Ltd